Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.3
4.1
Journals
Metabolites
Special Issues
Metabolic Syndrome in Neuroendocrine Tumors
share announcement

Metabolic Syndrome in Neuroendocrine Tumors

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Endocrinology and Clinical Metabolic Research".

Deadline for manuscript submissions: closed (30 October 2022) | Viewed by 5988

Special Issue Editors

Dr. Roberta Modica

E-Mail Website
Guest Editor
Endocrinology Unit, Department of Clinical Medicine and Surgery, ENETS Center of Excellence, University “Federico II” of Naples, 80131 Naples, Italy
Interests: neuroendocrine neoplasms; neuroendocrine tumors; multiple endocrine syndromes (MEN1 and MEN2); pheochromocytoma and paraganglioma; medullary thyroid cancer
Special Issues, Collections and Topics in MDPI journals
Dr. Anna La Salvia

E-Mail Website
Guest Editor
National Center for Drug Research and Evaluation, National Institute of Health (ISS), Rome, Italy
Interests: neuroendocrine tumors; drug development; clinical research; translational research; precision oncology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Neuroendocrine neoplasms (NEN) comprise a heterogeneous group of malignancies with variable clinical behaviour, with a significant increase in incidence observed over the past four decades. NEN can be sporadic or associated with inherited syndromes, mainly arise in the gastroenteropancreatic tract (GEP-NEN), but virtually any organ can be affected. Advances in understanding the genetics and biology of NEN have been achieved, but there is still a lot to explore. Metabolic syndrome (MetS) and its features such as dyslipidemia, type 2 diabetes mellitus (T2DM) and obesity are also steadily increasing worldwide and have already been evaluated as potential risk factors for cancer development and recurrence. Available data regarding the relationship between NEN and MetS are limited and mainly related to GEP-NEN. Exploring the mechanisms underlying the association among the metabolic alterations that define MetS and NEN could improve our knowledge of these diverse neoplasms and importantly could also allow us to identify new potential therapeutic targets, leading to improving patients’ outcomes.

Dr. Roberta Modica
Dr. Anna La Salvia
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neuroendocrine neoplasms
  • neuroendocrine tumors
  • metabolic syndrome
  • metabolism
  • diabetes
  • obesity
  • hypertension
  • cardio-metabolic risk
  • risk factor
  • cancer

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

15 pages, 853 KiB  
Review
Exploring the Relationship between Obesity, Metabolic Syndrome and Neuroendocrine Neoplasms
by Xiaoyang Lan, Nicola Fazio and Omar Abdel-Rahman
Metabolites 2022, 12(11), 1150; https://doi.org/10.3390/metabo12111150 - 21 Nov 2022
Cited by 1 | Viewed by 1380
Abstract
Obesity is a major burden for modern medicine, with many links to negative health outcomes, including the increased incidence of certain cancer types. Interestingly, some studies have supported the concept of an “Obesity Paradox”, where some cancer patients living with obesity have been [...] Read more.
Obesity is a major burden for modern medicine, with many links to negative health outcomes, including the increased incidence of certain cancer types. Interestingly, some studies have supported the concept of an “Obesity Paradox”, where some cancer patients living with obesity have been shown to have a better prognosis than non-obese patients. Neuroendocrine neoplasms (NENs) are malignancies originating from neuroendocrine cells, in some cases retaining important functional properties with consequences for metabolism and nutritional status. In this review, we summarize the existing evidence demonstrating that obesity is both a risk factor for developing NENs as well as a good prognostic factor. We further identify the limitations of existing studies and further avenues of research that will be necessary to optimize the metabolic and nutritional status of patients living with NENs to ensure improved outcomes. Full article
(This article belongs to the Special Issue Metabolic Syndrome in Neuroendocrine Tumors)
14 pages, 1738 KiB  
Review
Impact of Diabetes Mellitus in Patients with Pancreatic Neuro-Endocrine Tumors: Causes, Consequences, and Future Perspectives
by Lorena Hernandez-Rienda, Maria Isabel del Olmo-García and Juan Francisco Merino-Torres
Metabolites 2022, 12(11), 1103; https://doi.org/10.3390/metabo12111103 - 11 Nov 2022
Cited by 3 | Viewed by 2672
Abstract
Diabetes mellitus (DM) and pancreatic neuroendocrine tumors (pNETs) are two entities closely linked together. DM has been described as a risk factor for the development of pNETs and for the aggressiveness of the disease. On the other hand, DM due to pNETs is [...] Read more.
Diabetes mellitus (DM) and pancreatic neuroendocrine tumors (pNETs) are two entities closely linked together. DM has been described as a risk factor for the development of pNETs and for the aggressiveness of the disease. On the other hand, DM due to pNETs is frequently undiagnosed or misclassified as type 2 DM when it is due to type 3 DM. In addition, metformin, a commonly prescribed drug for type 2 DM, has an antiproliferative property and is gaining increasing attention as an antitumor agent. This review article presents the findings published in the last few years on pNETs and DMs. Emphasis will be placed on DM as a risk factor, pNET as a risk factor for the development of type 3 DM, the management of type 3 DM on pNET, and DM as a prognostic factor in patients with pNET, as well as the future clinical implications of DM in these patients. The coexistence of DM and pNET is extensively presented. It is important to perform future clinical trials, which are necessary to establish the role of metformin on pNET disease. Increasing awareness among professionals managing pNET on the importance of a correct DM diagnosis and management of the disease must be a priority due to the implications on mortality and comorbidities it may have in these patients. Full article
(This article belongs to the Special Issue Metabolic Syndrome in Neuroendocrine Tumors)
►▼ Show Figures

Figure 1

11 pages, 2862 KiB  
Review
Lipid Metabolism and Homeostasis in Patients with Neuroendocrine Neoplasms: From Risk Factor to Potential Therapeutic Target
by Roberta Modica, Anna La Salvia, Alessia Liccardi, Giuseppe Cannavale, Roberto Minotta, Elio Benevento, Antongiulio Faggiano and Annamaria Colao
Metabolites 2022, 12(11), 1057; https://doi.org/10.3390/metabo12111057 - 02 Nov 2022
Cited by 5 | Viewed by 1525
Abstract
Lipid metabolism is known to be involved in tumorigenesis and disease progression in many common cancer types, including colon, lung, breast and prostate, through modifications of lipid synthesis, storage and catabolism. Furthermore, lipid alterations may arise as a consequence of cancer treatment and [...] Read more.
Lipid metabolism is known to be involved in tumorigenesis and disease progression in many common cancer types, including colon, lung, breast and prostate, through modifications of lipid synthesis, storage and catabolism. Furthermore, lipid alterations may arise as a consequence of cancer treatment and may have a role in treatment resistance. Neuroendocrine neoplasms (NENs) are a heterogeneous group of malignancies with increasing incidence, whose mechanisms of cancer initiation and progression are far from being fully understood. Alterations of lipid metabolism may be common across various cancer types, but data about NENs are scattered and heterogeneous. Herein, we provide an overview of the relevant literature on lipid metabolism and alterations in NENs. The available evidence both in basic and clinical research about lipid metabolism in NENs, including therapeutic effects on lipid homeostasis, are summarized. Additionally, the potential of targeting the lipid profile in NEN therapy is also discussed, and areas for further research are proposed. Full article
(This article belongs to the Special Issue Metabolic Syndrome in Neuroendocrine Tumors)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop